Annoviant

Annoviant, headquartered in Alpharetta, Georgia, is a small medical technology company with five employees. The company was formerly known as TGen Tech and has generated approximately $1 million in revenue. Annoviant is focused on developing innovative medical technologies to tackle major healthcare challenges. Currently, the company is investigating the potential of its breakthrough technology, TxGuard™, in cardiovascular applications, particularly for patients with congenital heart disease. TxGuard™ is designed to grow with patients, offering a potentially transformative solution. Annoviant differentiates itself through its commitment to developing life-saving technologies that address critical healthcare needs. The company's focus on cardiovascular applications, particularly for congenital heart disease, highlights its dedication to improving patient outcomes in a specialized area. For more information, please visit Annoviant's website at annoviant.com.